tbuckley/cabot-search huggingface dataset:
Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).
Authors: Martin Reck, Anders Mellemgaard, Sergey V. Orlov, Maciej Jerzy Krzakowski, Joachim Von Pawel, Maya Gottfried, Igor Bondarenko, Mei-Lin Liao, Jose Barrueco, Julia Hocke, Rolf Kaiser, Silvia Novello, Jean-Yves Douillard
Journal: Journal of Clinical Oncology (2014)

8100 Background: Antiangiogenic treatments, including monoclonal antibodies and TKIs, have shown activity in tumors; however, their use is limited in part by their characteristic side effects (eg, bleeding, thrombosis, perforation, serious skin reactions, hypertension). N is an oral, twice-daily, triple angiokinase inhibitor. Here we extend our investigation of the LUME-Lung 1 study (ClinicalTrials.gov NCT00805194) and evaluate whether adding N to standard second-line D increases the frequency of characteristic adverse events (AEs) associated with antiangiogenic agents and whether these AEs restrict the use of N. Methods: LUME-Lung 1, a randomized, placebo-controlled Phase III trial investigating N + D in patients with advanced NSCLC after failure of first-line chemotherapy, demonstrated significant PFS improvement regardless of histology and showed significant survival improvement for patients with adenocarcinoma histology. The incidence and intensity of antiangiogenic-associated AEs according to the common terminology criteria for AEs (CTCAE version 3.0) were evaluated in all patients who received at least one dose of N, D, or Placebo (Pl). Results: AEs linked to VEGF inhibition that were more common (≥2% difference) in the N vs Pl arm were bleeding (all grades: 14.1% vs 11.6%; grade ≥3: 2.3% vs 1.8%) and hypertension (all grades: 3.5% vs 0.9%; grade ≥3: 0.6% vs 0.2%). When we compared histologic differences in antiangiogenic-associated AEs, we found nominal differences. More bleeding events were reported for N- treated squamous cell carcinoma (SCC) patients (all grades: 17.1% vs 10.9%; grade ≥3: 2.9% vs 1.3%) than for those with adenocarcinoma (all grades: 10.9% vs 11.1%; grade ≥3: 1.5% vs 1.3%). Fatal bleeding events, serious skin reactions, thrombosis, and perforations occurred at a low frequency and were balanced between both arms, regardless of histology. Conclusions: We demonstrated that adding N to standard second-line D for NSCLC therapy did not increase the frequency of AEs associated with antiangiogenic treatment to a relevant extent, except for grade 1-2 bleeding events in SCC patients. These AEs were balanced regardless of histology in LUME-Lung 1. Clinical trial information: NCT00805194.
Diagnostic and Prognostic Value of Factor VIII Binding Antibodies in Acquired Hemophilia A: Data from the GTH-AH 01/2010 Study
Authors: Andreas Tiede, Sonja Werwitzke, Ulrich Geisen, Ulrike Nowak-Göttl, Hermann Eichler, Bernhard Stephan, Ute Scholz, Holstein Katharina, Robert Klamroth, Paul Knöbl, Angela Huth-Kühne, Barbara Bomke
Journal: Blood (2015)
227P Efficacy of conversional radical surgery following upfront docetaxel, oxalipaltin and S1 (DOS) regimen for advanced gastric cancer with a single non-curable factor
Authors: Y. Wang, Y. Yu, C. Yuehong, Q. Li, J. Hou, Y. Ji, Y. Sun, Z. Shen, F. Liu, N. Zhao, T. Liu
Journal: Annals of Oncology (2016)
Discovery of Subtype-Specific Mirnas and New MiR-Genes In Pediatric Acute Lymphoblastic Leukemia
Authors: Diana Schotte, Renee X de Menezes, Farhad Akbari Moqadam, Ellen Lange-Turenhout, Ronald W Stam, Jules PP Meijerink, Rob Pieters, Monique L. Den Boer
Journal: Blood (2010)
Single-Cell Signatures Link Ambient Air Pollution to Remodeling of the Immune System in Asthmatics
Authors: Hua Fan-Minogue, Kinjal Hew, Shu-Chen Lyu, Unni Nygaard, Frederick Lurmann, Elizabeth Noth, John Balmes, Helene Margolis, Katharine Hammond, Ellen Eisen, Rachel Miller, Kari Nadeau
Journal: Journal of Allergy and Clinical Immunology (2017)
Response to Nasal Challenge Correlates with Seasonal Outcomes during Grass Pollen Immunotherapy with Either Subcutaneous or Sublingual Immunotherapy
Authors: Guy Scadding, Aarif O. Eifan, Moises A. Calderon, Mohamed H. Shamji, Martin Penagos, Peter A. Wurtzen, Michelle L. Sever, Henry T. Bahnson, Kaitie Lawson, Kristina M. Harris, Tielin Qin, Noha Lim, Audrey Plough, Nadia K. Tchao, Alkis Togias, Stephen R. Durham
Journal: Journal of Allergy and Clinical Immunology (2017)
How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
Authors: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, Outi Hirvonen, Tarja Laitinen, Sirkku Jyrkkiö, Laura L. Elo
Journal: European Urology (2017)
Distance From Home to the Nearest Tobacco Outlet May Not Reflect the True Accessibility
Authors: Ka Yiu Lee, Michael Huen Sum Lam, Paul H. Lee
Journal: JAMA Internal Medicine (2017)

To the Editor In their Original Investigation in a recent issue of JAMA Internal Medicine, Pulakka et al1 examined the association between walking distance from home to the nearest tobacco outlet and smoking cessation and relapse. We noticed several limitations that should be considered.
Whole-Exome Sequencing in Myelodysplastic Syndromes with 5q Deletion
Authors: Vera Adema, Laura Palomo, María Díez-Campelo, Mar Mallo, Leonor Arenillas, Elisa Luño, Albert Perez-Ladaga, Shawn Yost, Lurdes Zamora, Paula Gomez-Marzo, Blanca Xicoy, Carmen Pedro, María Consuelo Cañizo, Carmen Sanzo, Rosario Lopez, Angelina Lemes, Jose Maria Raya, Eduardo Rios, Montserrat Arnan, Raquel Paz, Joaquin sanchez-Garcia, Lourdes Florensa, Ivo G. Gut, Monica Bayes, Rafael Bejar, Francesc Sole
Journal: Blood (2014)
18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.
Authors: Saad Z Usmani, Sarah Waheed, Alan Mitchell, John Crowley, Antje Hoering, Nathan M Petty, Joshua Epstein, Christoph Heuck, Shmuel Yaccoby, Donald Johann, Frits van Rhee, Bart Barlogie
Journal: Blood (2012)
Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients
Authors: L. Verlingue, C. Massard, A. Hollebecque, E. Castanon Alvarez, S. Postel-Vinay, E. Angevin, J.-P. Armand, S. Aspeslagh, A. Varga, B. Ratislav, A. Gazzah, J.-M. Michot, L. Lacroix, T. De Baere, A. Marabelle, J.-C. Soria
Journal: Annals of Oncology (2016)
HIV1-positive men who have sex with men (HIV1-MSM) knowledge and attitudes towards anal cancer screening: A cross-sectional study
Authors: A. Vanhaesebrouck, S. Pernot, J. Pavie, M.L. Lucas, L. Collias, H. Péré, J. Taieb, S. Grabar, L. Weiss
Journal: Annals of Oncology (2016)
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib
Authors: N. Lankheet, I.M. Desar, S.F. Mulder, D.M. Burger, C.M.L. van Herpen, W.T.A. van der Graaf, N.P. van Erp
Journal: Annals of Oncology (2016)
OS4.2 Radiological response assessment in the era of bevacizumab: RANO or volumetry? A report from the BELOB trial.
Authors: R. Gahrmann, M. van den Bent, B. van der Holt, R. Vernhout, W. Taal, M. Taphoorn, J. de Groot, L. Beerepoot, B. Jasperse, M. Smits
Journal: Neuro-Oncology (2016)

Purpose:
Response assessment in brain tumors is currently done with the 2D Response Assessment in Neuro-Oncology (RANO) criteria. However, bevacizumab-treated patients may show pseudoresponse on contrast enhanced T1w- (T1w+C), and more infiltrative growth on T2w/FLAIR images at recurrence. We assessed whether in recurrent glioblastoma volumetric methods improve assessment of progressive disease (PD) over the RANO criteria, by correlating PD with overall survival (OS), the golden endpoint in oncology studies.
CLL Mesenchymal Stromal Cells Have Decreased Replicative Potential and Senescent Phenotype: Clinical and Biologic Implications
Authors: Wei Ding, Charla Secreto, Xiaosheng Wu, Esteban Braggio, Yuji Zhang, Stephanie A. Smoley, Tait D. Shanafelt, Jaime Davila, Timothy G Call, Daniel L. Van Dyke, Diane F. Jelinek, Neil E. Kay
Journal: Blood (2014)
Hunt is urged to end GP charges for domestic violence legal aid letters
Authors: Gareth Iacobucci
Journal: BMJ (2017)

A letter to England’s health secretary, Jeremy Hunt, has urged him to intervene to stop victims of domestic abuse being charged up to £175 (€203; $217) to obtain medical letters that allow them to access legal aid.1

The letter was signed by 16 “police and crime commissioners”—locally elected officials whose job it is to hold police forces to account. It said that some GP practices were charging victims for written proof that they had been …
The Bruton Tyrosine Kinase Inhibitor, PCI-32765, Inhibits Activation and Proliferation of Human Chronic Lymphocytic Leukemia Cells in the NSG Xenograph Mouse Model of the Tissue Microenvironment
Authors: Sarah E. M. Herman, Xiameng Sun, Joseph J. Buggy, Georg Aue, Patricia Perez-Galan, Adrian Wiestner
Journal: Blood (2011)
Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin (Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with Relapsed (rel) or Refactory (ref) Multiple Myeloma.
Authors: Asher Alban Chanan-khan, Swaminathan Padmanabhan, Kena C. Miller, Laurie Musiel, Jihnhee Yu, Zale P. Bernstein, Rami Manochakian, Myron S. Czuczman
Journal: Blood (2006)
Efficient Gene Transfer into Primate ES Cells and Stable Transgene Expression during Hematopoietic Differentiation by Sendai Virus Vector.
Authors: Yutaka Hanazono, Kyoko Sasaki, Makoto Inoue, Hiroaki Shibata, Yasuji Ueda, Mamoru Hasegawa, Keiya Ozawa
Journal: Blood (2004)
Investigation between OS and clinical and laboratory findings at the time of administering chemotherapy in ED-SCLC
Authors: Yuki Akazawa, Yuko Abe, Kohichi Ogawa, Yuichi Mitsui, Yuya Shirai, Shigetoshi Shimamoto, Kiyonobu Ueno, Yoshiro Tanio
Journal: Annals of Oncology (2016)
Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study
Authors: Hiroyuki Mochizuki, Satoshi Kusuda, Kenji Okada, Shigemi Yoshihara, Hiroyuki Furuya, Eric A. F. Simões, Hideomi Asanuma, Hiroshi Yoshida, Masahiko Katayose, Takashi Imamura, Hiroshi Suzumura, Youko Honma, Jichi Medical, Kenichi Maruyama, Yasushi Ohki, Koji Ozasa, Akiyoshi Nariai, Atsushi Uchiyama, Hideko Uryu, Shigeharu Hosono, Masatoshi Kondo, Yasuharu Kawase, Kazunari Ikeda, Kazunari Ikeda, Atsushi Naito, Yuki Minami, Tomohiko Nakamura, Atsushi Baba, Yoshihisa Nagayama, Hisashi Kaneda, Shigeru Ohki, Masami Shiraii, Yuto Henmi, Chizuko Suzuki, Kuniko Ieda, Taihei Tanaka, Yoshinori Kono, Kashiro Nisizawa, Fusako Niwa, Hisato Ito, Yasuyuki Tokunaga, Yoshinobu Takada, Yoshihide Nishikawa, Ikuo Nagata, Yasuhisa Kajino, Shinichi Watabe, Hiroyuki Yoshio, Nobumasa Takahashi, Nobutaka Sasaki, Michiko Hayashidani, Hiroshi Tateishi, Kenji Matsushita, Masatoshi Nakamura, Hideki Nakayama, Go Yamamoto, Noriaki Kanemitsu, Toshimitsu Takayanagi, Ayumi Sato, Satoshi Ibara
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: Respiratory syncytial virus (RSV) induces not only infantile recurrent wheezing but also potentially atopic asthma.Objectives: To test the effect of RSV infection on development of subsequent atopic asthma, we evaluated whether palivizumab, an anti-RSV monoclonal antibody, by preventing severe RSV disease in the first year of life, could impact subsequent recurrent wheezing and atopic asthma at 6 years of age.Methods: During the 2007 to 2008 RSV season, the decision to administer palivizumab was made based on standard medical practice and an observational prospective multicenter (n = 52) case–control study in preterm infants with a gestational age between 33 and 35 weeks followed from 0 to 3 years (preceding Committee on Recurrent Wheezing study). The 52 investigators at hospitals then followed these subjects until 6 years of age, reported here (Effects of Preventive Treatment for Respiratory Syncytial [RS] Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants; Scientific Committee for Elucidation of Infantile Asthma). Parents of study subjects reported the infants’ physicians’ assessment of recurrent wheezing, using a report card and a novel mobile phone–based reporting system using the Internet. The primary endpoint was the incidence of atopic asthma.Measurements and Main Results: Of 444 preterm infants enrolled, 349 received palivizumab during the first year of life. At 6 years, atopic asthma was not different in the groups: 15.3 and 18.2% of infants in the treated and untreated groups, respectively (P = 0.57). On the other hand, physician-diagnosed recurrent wheezing was observed in 15.3 and 31.6% in the treated and untreated groups, respectively (P = 0.003).Conclusions: Palivizumab prophylaxis administered to preterm infants did not suppress the onset of atopic asthma but resulted in a significantly lower incidence of recurrent wheezing during the first 6 years.Clinical trial registered with www.clinicaltrials.gov (NCT 01545245).
In situ heart valve tissue engineering using a bioresorbable elastomeric implant – From material design to 12 months follow-up in sheep
Authors: Jolanda Kluin, Hanna Talacua, Anthal I.P.M. Smits, Maximilian Y. Emmert, Marieke C.P. Brugmans, Emanuela S. Fioretta, Petra E. Dijkman, Serge H.M. Söntjens, Renée Duijvelshoff, Sylvia Dekker, Marloes W.J.T. Janssen-van den Broek, Valentina Lintas, Aryan Vink, Simon P. Hoerstrup, Henk M. Janssen, Patricia Y.W. Dankers, Frank P.T. Baaijens, Carlijn V.C. Bouten
Journal: Biomaterials (2017)

The creation of a living heart valve is a much-wanted alternative for current valve prostheses that suffer from limited durability and thromboembolic complications. Current strategies to create such valves, however, require the use of cells for in vitro culture, or decellularized human- or animal-derived donor tissue for in situ engineering. Here, we propose and demonstrate proof-of-concept of in situ heart valve tissue engineering using a synthetic approach, in which a cell-free, slow degrading elastomeric valvular implant is populated by endogenous cells to form new valvular tissue inside the heart. We designed a fibrous valvular scaffold, fabricated from a novel supramolecular elastomer, that enables endogenous cells to enter and produce matrix. Orthotopic implantations as pulmonary valve in sheep demonstrated sustained functionality up to 12 months, while the implant was gradually replaced by a layered collagen and elastic matrix in pace with cell-driven polymer resorption. Our results offer new perspectives for endogenous heart valve replacement starting from a readily-available synthetic graft that is compatible with surgical and transcatheter implantation procedures.
Feedback to doctors cuts unnecessary antibiotic use in hospitals, review finds
Authors: Susan Mayor
Journal: BMJ (2017)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Feedback to doctors cuts unnecessary antibiotic use in hospitals, review finds Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours
Authors: S. Domchek, Y.-J. Bang, G. Coukos, K. Kobayashi, N. Baker, E. McMurtry, W. Song, B. Kaufman
Journal: Annals of Oncology (2016)
A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients with Haemoglobinopathies, Myelodysplastic Syndromes or Other Anaemias Treated with Deferasirox (the MILE study CICL670AAU01) – Results of An Interim Analysis At a Planned Sample Size Reassessment,
Authors: P. Joy Ho, Lay Tay, Juliana Teo, Paula Marlton, Andrew Grigg, Tim St. Pierre, Greg Brown, Othon L Gervasio, Donald K Bowden
Journal: Blood (2011)
Successful Treatment of HU-Refractory Polycythemia Vera with Atorvastatin and Low Dose Hydroxyurea. Results from a Pilot Study in Bolivia
Authors: Ricardo Amaru, Ariel Amaru, Hortensia Miguez, Gina Torres, Josue Mamani, Maria Aguilar, Heriberto Cuevas
Journal: Blood (2015)
Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: a multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27)
Authors: E. Samalin, Cdela Fouchardiere, S. Thezenas, V. Boige, H. Senellart, R. Guimbaud, J. Taieb, E. Francois, M.-P. Galais, A. Adenis, A. Lievre, L. Dahan, F. Di Fiore, F. Boissiere, E. Crapez, F. Bibeau, A. Ho-Pun-Cheung, S. Poujol, T. Mazard, M. Ychou
Journal: Annals of Oncology (2016)
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors
Authors: Vamsi K Kota, Elliott F. Winton, Martha Arellano, Anand Jillella, Morgan L. McLemore, Fuad El Rassi, H Jean Khoury
Journal: Blood (2015)
Dasatinib (SPRYCEL®) in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase (CML-CP).
Authors: Jorge Cortes, S. O’Brien, D. Jones, G. Borthakur, F. Giles, C. Nicaise, H.M. Kantarjian
Journal: Blood (2006)
Difference in outcomes among patients undergoing open versus laparoscopy-assisted approach for gastric cancer: A multi-institutional analysis.
Authors: Gaya Spolverato, Vicente Valero, Yuhree Kim, Aslam Ejaz, Malcolm Hart Squires, George A. Poultsides, Ryan C. Fields, Mark Bloomston, Sharon M. Weber, Konstantinos Ioannis Votanopoulos, David J. Worhunsky, Doug S. Swords, Linda X. Jin, Carl Richard Schmidt, Alexandra W. Acher, Neil Saunders, Clifford Suhyun Cho, Shishir K. Maithel, Timothy M. Pawlik
Journal: Journal of Clinical Oncology (2014)

4082 Background: In the United States, gastric cancer is a relatively uncommon tumor. Overall surgical experience with minimally invasive surgery (MIS) has increased, however published reports on laparoscopic resection of gastric cancer are mostly limited to small, single institution experiences. Methods: Between 2000 and 2012, 880 patients who underwent surgical resection of a gastric cancer were identified from a multi-center database. Clinicopathological characteristics, receipt of peri-operative therapy, operative details, and oncologic outcomes were analyzed and defined. Results: Median patient age was 65.8 years and 42.6% (375/880) were female. Median tumor size at diagnosis was 4.0 cm (2.5-6.8 cm). A minority of patients received neoadjuvant therapy (207, 32.7%). Overall, 70 (8%) patients had a minimally invasive (MIS) approach: laparoscopic (60, 85.7%) and laparoscopic hand assist (10, 14.3%). Patients who underwent MIS resections were more likely to a smaller tumor (MIS: 3.0 cm vs. open: 4.5 cm) (p<0.001). MIS resections were associated with similar estimated blood loss (MIS: 150 cc vs. open: 250 cc, p=0.14) and similar operative time (MIS: 271 min vs. open: 232 min, p=0.07) compare to open surgery. An R0 resection was achieved in the overwhelming majority of patients (MIS: 98.6% vs. open: 90.9%; p=0.03). Post-operatively, MIS patients had a similar incidence of complications (MIS: 20% vs. open: 33.1%, p=0.07) and a similar length of stay (MIS: 7 d vs. open: 9 d, p=0.13) compare to open surgery patients. For the entire cohort, median recurrence-free survival was 27.34 months and median overall survival was 33.42 months. In analyzing the entire cohort, the overall 5-year survival of patients treated with MIS was 42.6% vs. 35.8% for patients treated with an open approach (p=0.05). In the propensity score-matched multivariate model, laparoscopy remained associated with an improved long-term overall (HR 0.34) survival (P<0.001). Conclusions: An MIS approach to select patients with gastric cancer is associated with a high R0 resection rate. The long-term oncological outcome following MIS is excellent and therefore the MIS approach should be considered.
Cryopreserved Ex-Vivo Expanded Murine Hematopoietic Progenitors Can Engraft Across MHC Barriers and Improve Survival In a Murine Model of Acute Radiation Syndrome.
Authors: Filippo Milano, Ian Nicoud, Daniel Weber, Shelly Heimfeld, Irwin D. Bernstein, Colleen Delaney
Journal: Blood (2010)
A randomized phase II study of pancrelipase in patients with gastrectomy to assess the prevention of weight loss
Authors: S. Tamura, H. Taniguchi, A. Takeno, K. Murakami, Y. Katsura, Y. Ohmura, A. Naito, Y. Kagawa, Y. Takeda, T. Kato
Journal: Annals of Oncology (2016)
Epidemiology of IgE-Mediated Allergy to Wheat Among Thai Children, Another Epidemic of Food Allergy in Asia.
Authors: Witchaya Srisuwatchari, Punchama Pacharn, Orathai Jirapongsananuruk, Nualanong Visitsunthorn, Pakit Vichyanond
Journal: Journal of Allergy and Clinical Immunology (2017)
BMET-14. RETROSPECTIVE ANALYSIS TO DETERMINE THE FREQUENCY OF SYMPTOMATIC NEW BRAIN METASTASES DURING ROUTINE MRI SURVEILLANCE POST-SRS OR -WBRT
Authors: Daniel Eichorn, Md Usman Ali, Varahi Trivedi, Roy Patchell, MD, Timothy Chen, MD, Shirnett Williamson, MD, Christina Maxwell
Journal: Neuro-Oncology (2016)

Initial SRS for treatment of brain metastases (mets) has been questioned due to higher distant-control failure rates compared with WBRT. WBRT has shown an association with increased toxicity and cognitive decline, yet overall survival (OS) rates are similar. Whether higher distant-control failure rates with SRS should be a chief consideration in choice of radiation technique, depends on whether new mets are symptomatic when identified through routine MRI screening. This review aims to determine the proportion of new brain mets that are symptomatic following initial radiation treatment (RT). We hypothesize that the majority of new mets are asymptomatic. From 2012-2015, 115 consecutive charts of patients treated with SRS, WBRT or both were reviewed for new met development during the first year post-treatment. Serial MRIs occurred 3-monthly. Chart reviewers and statisticians were blinded to the hypothesis. Data collected at each interval included MRI review, complete symptomatology, and treatment modalities. Median patient age was 64.6 years (43% male; 57% female). Most frequent primary tumor type was lung (49.5%). Mean OS was 9.8 months. Following initial treatment, 30/46 patients alive developed 94 new mets from 0-6 months (early). At 6-12 months (late), 19/29 patients alive developed 78 new mets. In total, 172 new brain mets were identified, 16 of which were symptomatic (9.3%). These 16 mets, identified in 8 patients, demonstrated neurological symptoms related to new tumor eloquence. Our study showed that following initial RT, most new brain mets are asymptomatic (90.7%) when identified on routine MRI. This suggests that distant tumor control might play a less significant role in initial radiation choice, since new mets can be treated before becoming symptomatic. Further, this could support delaying or avoiding WBRT in favor of upfront SRS, thus reducing toxicity and promoting better quality of life. A prospective trial is underway.